Cours suspendu

Communiqués Allakos Inc.

Actions

ALLK

US01671P1003

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 14/05/2025			Varia. 5j.	Varia. 1 janv.
0,3291 ^USD	-0,06%		-.--%	-

15/05/25	Allakos Inc. annonce la démission du Dr Robert Alexander, Ph.D., de son poste de PDG.	CI
15/05/25	Allakos Inc. annonce des changements au sein de sa direction	CI

Communiqués

02/04/25	Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share	GL
12/03/25	Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results	AQ
12/03/25	Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results	GL
27/01/25	Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring	AQ
27/01/25	Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring	GL
19/12/24	Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm	PR
18/11/24	Allakos : Termination of Material Agreement Form 8 K	PU
06/11/24	Allakos : Provides Business Update and Reports Third Quarter 2024 Financial Results Form 8 K	PU
06/11/24	Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results	AQ
10/10/24	Allakos : Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers Form 8 K	PU
10/10/24	Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers	GL
16/08/24	Allakos : Failure to Satisfy Listing Rule Form 8 K	PU
07/08/24	Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results	GL
25/06/24	Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile	GL
28/05/24	Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria	GL
09/05/24	Allakos Provides Business Update and Reports First Quarter 2024 Financial Results	GL
14/03/24	Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	GL
14/03/24	Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	AQ
26/02/24	Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024	GL
26/02/24	Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024	AQ
12/02/24	Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition	GL
12/02/24	Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition	AQ
16/01/24	Allakos Announces a Restructuring to Focus on Development of AK006	GL
16/01/24	Allakos Announces a Restructuring to Focus on Development of AK006	AQ
16/01/24	Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints	AQ